Aclarion Announces $9.4 Million Initial Public Offering

April 25, 2022
The healthcare technology company founded by UCSF researcher Jeffery Lotz, PhD, that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence, and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public...

Video Game Improves Cognitive Symptoms

April 14, 2022
Its first product, EndeavorRx was developed by Adam Gazzaley, Professor of Neurology, Physiology, and Psychiatry at the University of California, San Francisco, to help improve attention in children between the ages of 8 and 12 with attention deficit hyperactivity disorder, or ADHD. Following it...

Exai Bio shows Its Unique RNA-based Liquid Biopsy Strategy for Early Cancer Detection

April 12, 2022
Next-generation liquid biopsy company, Exai Bio, presented data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs (oncRNAs), and the validation of artificial intelligence (AI) profiling of oncRNAs to accurately detect cancers of diverse...

Mission Bio Launches Solid Tumor Solution on Tapestri Platform

March 31, 2022
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis launched by University of California research professor Adam Abate, today launched the Tapestri Solution for Solid Tumor Research.

NephroSant Launches Two-Year Study of 2,000 Kidney Transplant Recipients

March 22, 2022
 NephroSant, Inc. a biotechnology company dedicated to accelerating the assessment of early kidney damage with a mission to significantly improve global kidney health, announced the first patient has been enrolled into the Assessment of QSant™ for Underlying Allograft Rejection (AQUA) study. 

Pionyr Doses First Patient in Expansion Study

March 11, 2022
Pionyr Immunotherapeutics, a company founded by pathologist researcher Max Krummel from the University of California, is developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body's antitumor immunity by altering, or "tuning", immune cells within the tumor...

Akili Interactive Cracks The Top Ten

March 09, 2022
Akili Interactive makes Fast Company's top ten list for developing a digital therapeutic for ADHD. MORE

QSent Improves the Detection of Early Kidney Rejection

March 07, 2022
"We developed QSant to aid physicians in the early detection of rejection in order to protect patients from an untimely loss of a transplanted kidney" explained NephroSant Founder and University of California professor, Minnie Sarwal, MD, PhD. "Results from this RWD study provide important insights...

Video Game Improves Brain Function

March 04, 2022
EndeavorRx, the startup founded by UCSF neuroscientist Adam Gazzaley, has been cleared to help in improving attention function as measured by computer-based testing in children ages 8-12 years who have primarily inattentive or combined-type ADHD who struggle with maintaining attention. MORE